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Abstract
PSA (Promastigote Surface Antigen) belongs to a family of membrane-bound and secreted proteins present in several
Leishmania (L.) species. PSA is recognized by human Th1 cells and provides a high degree of protection in vaccinated mice.
We evaluated humoral and cellular immune responses induced by a L. amazonensis PSA protein (LaPSA-38S) produced in a
L. tarentolae expression system. This was done in individuals cured of cutaneous leishmaniasis due to L. major (CCLm) or L.
braziliensis (CCLb) or visceral leishmaniasis due to L. donovani (CVLd) and in healthy individuals. Healthy individuals were
subdivided into immune (HHR-Lm and HHR-Li: Healthy High Responders living in an endemic area for L. major or L. infantum
infection) or non immune/naive individuals (HLR: Healthy Low Responders), depending on whether they produce high or
low levels of IFN-c in response to Leishmania soluble antigen. Low levels of total IgG antibodies to LaPSA-38S were detected
in sera from the studied groups. Interestingly, LaPSA-38S induced specific and significant levels of IFN-c, granzyme B and IL-
10 in CCLm, HHR-Lm and HHR-Li groups, with HHR-Li group producing TNF-a in more. No significant cytokine response was
observed in individuals immune to L. braziliensis or L. donovani infection. Phenotypic analysis showed a significant increase
in CD4+ T cells producing IFN-c after LaPSA-38S stimulation, in CCLm. A high positive correlation was observed between the
percentage of IFN-c-producing CD4+ T cells and the released IFN-c. We showed that the LaPSA-38S protein was able to
induce a mixed Th1 and Th2/Treg cytokine response in individuals with immunity to L. major or L. infantum infection
indicating that it may be exploited as a vaccine candidate. We also showed, to our knowledge for the first time, the capacity
of Leishmania PSA protein to induce granzyme B production in humans with immunity to L. major and L. infantum infection.
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Introduction
Leishmania (L.) are intracellular protozoa that cause a wide
spectrum of human diseases, ranging from self-healing cutaneous
to lethal visceral leishmaniasis. Cutaneous leishmaniasis (CL) is
widely distributed in the Americas, North Africa, the Middle East
and Central Asia, causing considerable morbidity [1]. In Tunisia,
CL is zoonotic and is mainly due to L. major [2]. In Peru, L.
braziliensis is responsible for nearly all the zoonotic CL cases [3].
Anthroponotic Visceral Leishmaniasis (VL) due to L. donovani is
mainly distributed in the Indian subcontinent with over 300 000
annual cases [4], whereas zoonotic VL caused by L. infantum is
present mainly in Mediterranean basin, Middle east, central Asia
and Brazil with up to 50 000 annual cases [5–7]. Treatment of
leishmaniasis mainly relies on chemotherapy and the control of the
disease is challenged by serious side effects of existing drugs and
the widespread emergence of drug resistant strains. Several lines of
evidence are in favor of the feasibility of a vaccine in humans.
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Healing is generally associated with the development of a life-long
immunity to re-infection. Moreover, a large majority of immuno-
competent exposed individuals develop asymptomatic or subclin-
ical infections rather than a severe form of leishmaniasis
(symptomatic) and acquires a robust and durable immunity to
reinfection. Resistance to infection is based on a Th1 dominant
response with interferon (IFN)-c production resulting in macro-
phage activation and parasite killing [8–10]. In healed individuals,
it has been shown that recovery and resistance to re-infection also
correlate with the development of antigen-specific Th1 cell
responses and IFN-c production [11–14]. Based on these data,
one vaccine strategy developed against Leishmania infection has
been focusing on the use of Th1 responses elicited in immune
individuals by defined parasite antigens as indicators of protection.
A number of leishmanial proteins have been characterized and
evidences from studies in animal models indicate that variable
levels of protection can be achieved using defined protein as
vaccines [15–17]. However, significant differences between mice
and humans immune system, in both its innate and adaptive arms
exist [18]. Very few candidates have progressed beyond the
experimental stage and designing an effective vaccine against
leishmaniasis is still a matter of research. One of the candidate
vaccine antigens is the PSA which belongs to a unique Leishmania
family of membrane-bound and secreted proteins. PSA main
signature is a specific Leucin Rich Repeats known to be involved
in protein-protein interactions and in pathogen recognition [19]. It
is an abundant glycolipid-anchored protein on the surface of the
promastigote form of most Leishmania species [19–26]. A water-
soluble form released in promastigote culture supernatants of L.
major [24] and of L. infantum [26] has also been described. PSA is
involved in parasite attachment and invasion of macrophages [27].
It has been reported to induce Th1-mediated protection against
murine leishmaniasis when used as a vaccine [28,29]. PSA is also
specifically recognized by Th1 cells of humans with a history of
self-healing CL [30] and by human sera of VL patients [31]. This
protein is present in both promastigote and amastigote stages
[32,33] and the presence of PSA family was demonstrated in
several Leishmania species [19,21,34,35]. PSA proteins are strongly
over-expressed in metacyclic promastigotes suggesting an associ-
ation with the virulence status of the parasites [32]. The known
role of PSA proteins in resistance to complement lysis further
supports this hypothesis [36]. The interest for the PSA is also
supported by our previous [37,38] and recent studies (unpublished
data) showing that sera of dogs vaccinated with L. infantum
excreted/secreted antigens (ESA) in combination with MDP
(muramyl dipeptide), recognized immunodominant antigens be-
longing to PSA protein family, from L. infantum ESA (LiPSA-54S;
GenBank under Accession number: FJ974055) and from L.
amazonensis ESA (LaPSA-38S; GenBank accession number:
FJ974054). In the present study, the recombinant native form of
L. amazonensis PSA protein (LaPSA-38S), produced in a L. tarentolae
expression system was evaluated for its ability to induce cellular
and humoral immune responses. We took advantage of a multi-
disciplinary consortium to assess, using the same tools and samples
from individuals with acquired immunity to L. major, L. braziliensis,
L. infantum or L. donovani, for PSA immunogenicity and its potential
use as a vaccine candidate against the different forms of
leishmaniasis.
Materials and Methods
1. Ethics statement
The recruitment and sampling collection of different groups of
volunteers, was done in accordance with Good Clinical Practice
(GCP), based on the recommendations and approval of the local
ethical Committee of each Institute involved in this study (Institut
de Recherche pour le De´veloppement (IRD) for France (the
recruitment of blood donors and the sample collection were
performed at the EFs human blood bank of Bordeaux), Instituto
de Salud Carlos III (ISCIII) for Spain (Comite´ de e´tica de la
investigacion y de bienestar animal), National Institute of
Pathology (NIP) for India (Office of ethical committee VMMC
& SAFDARJANG hospital New Delhi and Indian council of
medical research), Instituto de Medicina Tropical ‘‘Alexander von
Humboldt’’ (IMTAvH) for Peru (comite´ de investigacion y e´tica de
la unidad de capacitacion) and Institut Pasteur de Tunis (IPT) for
Tunisia (Comite´ d’e´thique de l’Institut Pasteur de Tunis). A
written informed consent was obtained from all subjects involved
in this study.
2. Study population and samples
Well-characterized endemic foci, blood banks and medical
structures (hospitals, medical departments and public health
centers) were identified in each country (India, Peru, Spain,
France, and Tunisia). Human groups (cured individuals and
healthy individuals with no history of leishmaniasis but with a
probable asymptomatic infection and therefore considered as
immune) were recruited from endemic areas for VL and CL,
based on the following defined inclusion criteria (i) living in
endemic foci to L. major, L. infantum, L. braziliensis or L. donovani (ii)
well documented medical records for cured groups (iii) presence of
typical scars for cured CL group and (iv) high IFN-c response to
Soluble Leishmania Antigens (SLA) (.300 pg/ml) for healthy
individuals with a probable asymptomatic infection. Patients with
active CL or VL were identified in health structures in charge of
patient management and had specific clinical symptoms. Healthy
individuals recruited in low or non-endemic areas, or in blood
banks with no history of leishmaniasis and no or low IFN-c
response to SLA (,100 pg/ml) were considered as non immune/
naives. Exclusion criteria were immunosuppressive diseases other
than leishmaniasis, long term treatment and pregnancy. The
different human groups used in this study are detailed in table 1.
Heparinized blood was collected from a total of 104 donors and 82
controls (Table 1).
3. Production and purification of LaPSA-38S recombinant
protein
Genomic DNA of L. amazonensis (MHOM/BR/76/LTB-012/
clone 1), cultivated in RPMI 1640 medium (Gibco-BRL, UK) and
supplemented with 10% heat-inactivated FBS (Gibco-BRL, UK),
10 mM HEPES, 100 U/ml penicillin, and 100 mg/ml streptomy-
cin (Gibco-BRL, UK) at 26uC, was extracted by phenol:
chloroform: isoamyl alcohol extraction (1:1:1) and ethanol
precipitation. The LaPSA-38S gene (GenBank accession number:
FJ974054) was amplified with forward primer, F-PSA-38S (59-
CCATGGCGCAGTGCGTGCGTCGG-39) and reverse primer,
R-PSA-38S (59-GCGGCCGCGTGATGGTGATGGTGAT-
GATCGTGGTTCGCCAG-39), containing NcoI and NotI restric-
tion sites in each 59 end (underlined) by PCR reaction. The
purified PCR product was cloned in pCR2.1-TOPO TA vector
using TOPO TA cloning Kit (Invitrogen) following the manufac-
turer’s procedures. The transformed cells E. coli TOP10 (Invitro-
gen) were screened for the presence of recombinant plasmid with
the LaPSA-38S insert by gene-specific PCR and analysis with
NcoIand NotIrestriction enzymes and isolated positive clones were
sequenced. The insert was removed by NcoIand NotI digestion and
subcloned into the NcoI and NotI insertion site of Leishmania
expression vector pF4X1.4sat1 allowing selection with the
Leishmania PSA as a Human Vaccine Candidate
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antibiotic Nourseothricin (Jena Bioscience, Germany) to create the
recombinant pF4X1.4-LaPSA-38S plasmid. The resulting con-
struct, encoding a full sequence of LaPSA-38S secreted protein
fused to a C-terminus His6 tag. L. tarentolae promastigotes were
successfully maintained in continuous culture by successive
passages of 56105 flagellates/ml every week into 10 ml of
completely chemically defined medium (CDM/LP) free of serum,
macromolecules, proteins and cell contaminants as previously
described [39,40]. For stable integration of the expression cassette
into the 18S ribosomal RNA (ssu) locus, 10 mg of pF4X1.4sat1
plasmid containing LaPSA-38S gene was digested by SwaI
restriction enzyme. Transfections of L. tarentolae promastigotes
were performed by electroporation in 2 mm cuvettes using a Gene
Pulser II (Biorad) and a single pulse (5–6 msec) with the settings
450 V and 450 mF. After pulse, cells were transferred into a fresh
CDM/LP medium. 100 mg/ml of Nourseothricin was added 24 h
after electroporation to select stable transformants. After a week of
culture only nourseothricin-resistant cells survived. Transgenic
cells were selected as single colonies on the supplemented CDM/
LP-agar medium containing 100 mg/ml Nourseothricin. To
confirm the integration of the LaPSA-38S containing cassette into
the Leishmania genome, PCR was performed on the genomic DNA
of wild type and transgenic cells with ssu forward primer F3001
and aprt reverse primer A1715 (Jena bioscience, Germany). Mass
culture and protein purification were manufactured by Virbac in
GMP conditions. Culture amplifications were performed on
CDM/LP medium. The culture supernatant containing L.
amazonensis excreted secreted LaPSA-38S, released by the parasite
during its growth, was recovered at the late stationary phase of
growth. The only proteins contained in the medium were of
parasitic origin and were found with their native conformation
because they were naturally excreted-secreted by Leishmania
parasites. Excreted secreted PSA was purified from concentrated
culture supernatant by Ni-NTA affinity chromatography.
4. Preparation of total soluble Leishmania promastigote
antigens (TSLA)
All antigen extracts were prepared from promastigote stationary
phase parasite cultures of L. donovani, L. braziliensis, L. major and L.
infantum. Each consortium partner used local TSLA (L. major TSLA
in Tunisia, L. infantum TSLA in France and Spain, L. braziliensis
TSLA in Peru and L. donovani TSLA in India) and TSLA from L.
donovani (TSLA Ldd8) (MHOM/IN/80/Ldd8Cl2 L. donovani strain
(Ldd8)), as a standard preparation. TSLA were obtained from
washed parasites in 1x phosphate-buffered saline (PBS), centri-
fuged at 10006g/10 min at 4uC and supernatants were removed.
The pellets were resuspended in lysis buffer (50 mM Tris/5 mM
EDTA/HCl, pH7. 1 mL/16109 parasites), subjected to three
rapid freeze/thaw cycles followed and to three pulses of 20
seconds/40W with sonicator. Samples were centrifuged at 50006g
for 20 min at 4uC, and supernatants were collected, aliquoted and
stored at 280uC until use. Protein quantification was performed
using Bradford method.
5. Cell culture and stimulation
Peripheral blood mononuclear cells (PBMC) were isolated from
blood by density centrifugation through Ficoll-Hypaque (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden).
The cells were cultured in RPMI 1640 supplemented with 10%
heat inactivated FBS, 100 IU/mL penicillin, 100 mg/mL strepto-
Table 1. Study population.
Country Human groups* Number of individuals Parasite species
India CVLd 16 L. donovani
aVLd 25 L. donovani
HLR-I 19
Peru CCLb 8 L. braziliensis
aCLb 21 L. braziliensis
HLR-P 10
Tunisia CCLm 25 L. major
HHR-Lm 20 L. major
HHR-LiT 18 L. infantum
aVLiT 12 L. infantum
HLR-T 16
France HHR-LiF 8 L. infantum
HLR-F 28
Spain HHR-LiS 9 L. infantum
aVLiS 4 L. infantum
HLR-S 9
The recruitment and sampling collection (186 donors) of different groups (patients, cured, immunes without clinical symptoms and naives) were performed in endemic
and non-endemic areas in each country.
*CVLd: Cured Visceral Leishmaniasis due to L. donovani (India), aVLd: active Visceral Leishmaniasis due to L. donovani (India), HLR-I: Healthy Low Responders from India,
CCLb: Cured Cutaneous Leishmaniasis due to L. brasiliensis (Peru), aCLb: active Cutaneous Leishmaniasis due to L. brasiliensis (Peru), HLR-P: Healthy Low Responders
from Peru, CCLm: Cured Cutaneous Leishmaniasis due to L. major (Tunisia), HHR-Lm: Healthy High Responders living in an endemic area for L. major (Tunisia), HHR-LiT:
Healthy High Responders living in an endemic area for L. infantum (Tunisia), aVLiT: active Visceral Leishmaniasis due to L. infantum (Tunisia), H-T: Healthy Low
Responders from Tunisia, HHR-LiF: Healthy High Responders living in an endemic area for L. infantum (France), HLR-F: Healthy Low Responders from France, HHR-LiS:
Healthy High Responders living in an endemic area for L. infantum (Spain), aVLiS: active Visceral Leishmaniasis due to L. infantum (Spain), HLR-S: Healthy Low
Responders from Spain.
doi:10.1371/journal.pone.0092708.t001
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mycin, 2 mM L-glutamin, 50 mM 2-mercaptoethanol, 1 mM
sodium pyruvate and 1X amino acid non essential. Briefly, cells
were plated in 96 well (TPP, Switzerland) and were kept with
media alone (unstimulated) or stimulated with 10 mg/mL of
Phytohemagglutinin (PHA) (Sigma-Aldrich) as a positive control or
with TSLA (10 mg/mL) or with LaPSA-38S (10 mg/mL), in a
5%CO2 humidified atmosphere at 37uC for 5 days.
6. Cytometric Bead Array assay (CBA)
IFN-c, granzyme B, tumor necrosis factor-alpha (TNF-a) and
Interleukin-10 (IL-10), were detected and quantified from culture
supernatants (50 ml) of PBMC exposed for 120 h to the following
stimuli: PHA-M (10 mg/ml), TSLA (10 mg/ml) or LaPSA-38S
(10 mg/ml), using the BD CBA Human Soluble Protein Flex Set
system and according to the instructions of the manufacturer (BD
Biosciences). It should be noted that granzyme B was not analyzed
in individuals immune to L. braziliensis infection. In order to
quantitate samples, the BD CBA Human Soluble Protein Flex
Standard was performed for each cytokine and in each exper-
iment. Data were acquired by flow cytometry (FACSCalibur or
FACSCanto) using 2-color detection. Flow Cytometric Analysis
Program Array (FCAP Array; BD Biosciences) software was
required for analyzing samples [41].
7. Cell phenotyping
Freshly isolated PBMC were stimulated with PMA (50 ng/ml)/
ionomicyn (1026 M) or PHA at 10 mg/ml for 6 h (positive control)
or with TSLA at 10 mg/ml or with LaPSA-38S at 10 mg/ml for
120 h and, or kept with medium alone. Cells were treated with
Golgistop (BD Biosciences) for the last 6 hours of culture, then
washed and incubated with antibodies: FITC CD3, PerCPcy5.5
CD4, APC-H7 CD8 or PerCPcy5.5 CD8, and PE-Cy7 CD69 or
PE CD69 (BD Biosciences), for 20 minutes at 4uC. For
intracellular IFN-c detection, cells were fixed and permeabilized
using BD Cytoperm/cytofix plus kit (BD Biosciences) according to
manufacturer’s instructions and labeled with PE-anti-IFN-c mAb
(intracellular formulation) (BD Biosciences). Analysis was per-
formed with FACSCalibur using CellQuest Pro software or FACS
canto II flow cytometer using DIVA software. FITC mouse IgG1,
PerCPCy5.5 mouse IgG1, mouse IgG1PE, PE mouse IgG2a
(intracellular formulation) (Biosciences) were used as isotype
controls for acquisition by FACSCalibur. For acquisition by
FACSCanto, BD CompBeads Set Anti-Mouse Ig, k (Anti-Mouse
Ig, k/Negative Control (FBS) Compensation Particles Set) (BD
Biosciences) were used.
8. Detection of antibodies specific for LaPSA-38S
An enzyme-linked immunosorbent assay (ELISA) test was
performed to detect specific antibodies to TSLA Ldd8 and
LaPSA-38S in individual serum samples from the different studied
groups (Table 2). In order to improve antibodies detection, ELISA
protocol was optimized by combining antigens concentrations and
anti-serum dilutions. Briefly, 96 wells plates (NuncMaxisorp
Immuno Plates, PolyLabo, Strasbourg, France) were coated with
100 ml/well of 2 or 5 mg/ml LaPSA-38S and TSLA overnight at
4uC. Plates were washed three times with PBS, 0.1% Tween 20
(PBS-T), pH 7.4 and blocked with 200 ml/well of PBS containing
0.1% Tween 20 and 3% BSA for 1 h at 37uC. After washing with
PBS-T, diluted sera (1/100, 1/150 and 1/200 in PBS-T) were
added (100 ml/well) and incubated for 1h30 at 37uC. Plates were
then washed with PBS-T and 100 ml/well of diluted HRP-
conjugated anti-human IgG in washing buffer were added for
30 min at 37uC (1/5000). Plates were developed with the 100 ml/
well of Sigma Fast o-phenylene diamine dihydrochloride (OPD) for
T
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15 min. The reaction was stopped with 50 ml/well of 2 N HCl.
The absorbance was measured at 492 nm. All sera were tested in
duplicate/triplicate, and the mean value was recorded.
9. Statistical analysis
Data from all partners were collected into a unique database
using the open source software Epidata 3.1 (Epidata Association,
Denmark http://www.epidata.dk/) and checked for consistency.
Individuals with missing data or exclusion criteria were deleted.
Data analysis was then performed with Stata statistical software
(StataCorp. 2009. Stata Statistical Software: Release 11. College
Station, TX: StataCorp LP.). We used non-parametric statistical
tests because of the low number of individuals in some groups and
of the heterogeneity of the standard deviation between groups.
Results are expressed as mean6standard deviation (SD) and a p-
value of ,0.05 was considered significant in all cases. In the
statistical analysis of cytokine level and phenotyping, we used
Wilcoxon signed-rank test to compare median levels of cytokines
or percentage of cells producing IFN-c after different stimulations
in paired data. Kruskal-Wallis rank test was used for inter-groups
analysis on normalized data after deducting the non-stimulated
value. Correlations were performed using pairwise correlations of
variance test. For humoral response analysis, we used Kruskal-
Wallis rank test to compare the median production of total IgG
between different stimulations. We estimated a threshold of
positivity for each country by calculating a cut-off using the
following formula:
tpos~mean level in naif groupð Þz 3sd level in naif groupð Þ:
Individuals with a level of IgG after stimulation higher than tpos
were considered as positive responders. For the statistical analysis
of sub-classes, results were compared only for positive individuals
Results
1. Production of LaPSA-38S in L. tarentolae
In this study, we generated a recombinant L. tarentolae strain
expressing exogenously the L. amazonensis LaPSA-38S gene. The
resulting construct encoded a full sequence of LaPSA-38S secreted
protein fused to a C-terminus His6 tag. LaPSA-38S protein purity
was assessed by SDS–PAGE using 12% polyacrylamide Ready
Gels (Bio-Rad) under reducing and non reducing conditions and
after silver staining. Immobilized Ni2+ affinity chromatography of
culture supernatant containing excreted/secreted extracts from
recombinant L. tarentolae, yielded a preparation featuring a purified
recombinant LaPSA-38S protein migrating as a 45 kDa species in
SDS–PAGE (Figure 1). The extra band observed in figure 1 was
identified as a dimer form of LaPSA-38S as suggested by a
proteomic study of purified LaPSA-38S using a combination of 1D
gel electrophoresis and LC-MS/MS (coupling between liquid
chromatography and tandem mass spectrometry) (Bras-Gonc¸alves
et al., manuscript in preparation).
2. IFN-c, granzyme B, TNF-a, and IL-10 levels in response
to LaPSA-38S protein in immune individuals
The supernatants of TSLA or LaPSA-38S-stimulated PBMC
were assayed for IFN-c, granzyme B, TNF-a and IL-10
production (Figure 2, Figure 3). PBMC were isolated from (i)
individuals cured from L. major (CCLm), L. braziliensis (CCLb) or L.
donovani (CVLd) infection, (ii) healthy individuals living in endemic
areas and showing high IFN-c response to TSLA, considered as
immune (HHR-Lm: Healthy High Responder living in endemic
area to L. major infection and HHR-Li, HHR living in endemic
area to L. infantum infection) and (iii) healthy individuals living in
low or non-endemic areas and showing low or no IFN-c response
to TSLA, considered as non immune/naive (HLR-T: Healthy
Low Responders from Tunis; HLR-F from France; HLR-S from
Spain; HLR-I from India and HLR-P from Peru). HHR-Li
individuals were recruited from three different areas (France:
HHR-LiF; Spain: HHR-LiS; Tunisia: HHR-LiT). LaPSA-38S
induced significant (when compared to non stimulated cultures,
p#0.003) and specific (when compared to corresponding naive
groups, p#0.01) levels of IFN-c in PBMC cultures of CCLm,
HHR-Lm, HHR-LiT and HHR-LiS (Mean 6 SD:
410.96913.1 pg/ml; 297.26306.9 pg/ml; 297.26423.2 pg/ml;
and 127.3679.1 pg/ml, respectively) (Figure 3a). No significant
IFN-c levels were detected in HHR-LiF or in naive groups HLR-
T, HLR-F or HLR-S. Low but significant IFN-c levels were
observed in CCLb and CVLd but also in their related naive
groups (HLR-P and HLR-I, respectively) (Figure 3a). LaPSA-38S
also induced significant and specific (p#0.04) granzyme B levels in
CCLm (235.76448.5), HHR-Lm (311.76345.9) and HHR-LiS
(492.86451) (Figure 3b). Granzyme B was not observed in naive
individuals. The levels of IFN-c and granzyme B were significantly
higher in the supernatants of all immune groups (CCLm:
3027.161356.4 and 2852.262035.9; CCLb: 740.261145.6,
granzyme B was not tested; CVLd: 740.16824.4 and
1511.161549.5; HHR-Lm: 3182.361198.4 and 2608.561818.1;
HHR-LiT: 3311.86818.3 and 3873.663401.8; HHR-LiF:
778.86299.3 and 364.56377.9; HHR-LiS: 2946.363773.7 and
747865902.6; respectively) compared to naives (p#0.007) after
Figure 1. SDS-PAGE and silver staining of purified recombinant
La-PSA38S protein expressed in L. tarentolae. Purified La-PSA38S
was separated by electrophoresis in a 12% SDS-PAGE and silver stained
under reducing (R) and non reducing (NR) conditions. The arrow
indicates the position of La-PSA-38S (45 kDa) and Molecular Weight
markers were marked in kDa.
doi:10.1371/journal.pone.0092708.g001
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TSLA Ldd8 stimulation (Figure 2a and b). It should be noted that
no significant differences were observed in IFN-c and granzyme B
responses between local TSLA and TSLA Ldd8 (Figure 2a and b).
Significant TNF-a levels (p#0.02) were observed in CCLb
(158.56216.2), CVLd (183.96271.4) and HHR-LiS (54.7646),
but also in some naive groups (HLR-P: 122.2672 and HLR-I:
253.76227.3) after LaPSA-38S stimulation (Figure 3c). TSLA
Ldd8 induced significant and specific TNF-a production (p#0.03)
in the same groups but also in HHR-LiT (CCLb: 149.36333.5;
CVLd: 47.2650.8; HHR-LiS: 275.26152.8 and HHR-LiT:
529.26359.9) (Figure 3c). PBMC from all immune and naive
groups showed significant levels of IL-10 (p#0.02) in response to
LaPSA-38S (immune groups: CCLm: 218.56184.3; CCLb:
797.861110; CVLd: 74.1654.9; HHR-Lm: 233.46241.7; HHR-
LiT: 104.5656.2; HHR-LiF: 87.9637.9; HHR-LiS: 175.76244.8;
naive groups: HLR-T: 73.5654.2; HLR-P: 449.46432.6; HLR-I:
78.8683.6; HLR-F: 71.8638.3; HLR-S: 24.5617.6) (Figure 3d).
IL-10 levels were significantly higher in CCLm, HHR-Lm and
HHR-LiT compared to corresponding naive groups (HLR-T) (p#
0.009). No IL-10 was observed in response to TSLA. No difference
was observed in the cytokine levels between immune groups, except
for LaPSA-38S-induced granzyme B levels which were significantly
higher in HHR-LiS compared to CCLm and HHR-Lm (p = 0.02
and 0.04, respectively).
Interestingly, strong positive correlations were found between
IFN-c and granzyme B production in CCLm group (r = 0.82;
p = 0.0000) and between granzyme B and IL-10 production in
HHR-LiS group (r = 0.7; p = 0.03), in response to LaPSA-38S.
IFN-c and granzyme B productions were also highly correlated in
response to TSLA Ldd8 in CCLm and HHR-Li groups (r = 0.67;
p = 0.0002 and r = 0.76; p = 0.01; respectively).
3. Phenotyping results
Phenotypic analysis of LaPSA-38S and TSLA Ldd8-specific
CD4+ and CD8+ cells producing IFN-c was performed in groups
in which we observed a significant LaPSA-38S-induced IFN-c
response (CCLm: n = 7, HHR-Lm: n = 6, HHR-LiS: n = 7) and in
naive individuals (HLR-S: n = 14) (Figure 4).
We showed a significantly higher percentage of CD4+ T cells
producing IFN-c (mean +/2 SD: 0.14 +/20.21%) among
activated CD4+ T cells (57.4+/213.9%), after LaPSA-38S
stimulation, only in CCLm individuals, in comparison to non
stimulated cultures (p = 0.049), (Figure 4, table 2). A strong positive
correlation was found between the percentage of IFN-c-producing
CD4+ T cells and IFN-c production in cell culture supernatants
assessed by CBA analysis, in response to LaPSA-38S antigen
(r = 0.97, p = 0.0003). No significant increase was observed in the
percentage of IFN-c-producing CD8+ T cells in tested immune
groups, in response to LaPSA-38S, compared to non stimulated
cultures (Figure 4). A significant increase was showed in the
percentage of IFN-c-producing CD4+ T cells in CCLm (0.37+/2
0.47%) and HHR-LiS (0.87+/20.74) and of IFN-c-producing
CD8+ T cells in HHR-LiS (0.53+/20.4), compared to non
stimulated cultures (p = 0.02), in response to TSLA Ldd8
stimulation (Figure 4).
4. Humoral response to LaPSA-38S
Anti-LaPSA-38S total IgG responses were analyzed by using
ELISA tests in sera from (i) patients with active disease (aVLd,
aVLiT, aVLiS, aCLb), (ii) cured individuals (CVLd, CCLm,
CCLb), (iii) healthy individuals with high IFN-c response to TSLA
Ldd8 as immune with no clinical symptoms (HHR-Lm, HHR-LiT,
HHR-LiF, HHR-LiS) and healthy individuals with low IFN-c
response to TSLA Ldd8 as naı¨ve controls (Table 3). The cut-off
value of reactivity for LaPSA-38S antigen was calculated as the
mean plus 3 SD of the OD values observed in naive controls from
each country. These cut-off values allowed us to distinguish
between positive and negative sera and consequently to estimate
performance parameters of each ELISA test (Table 3). Globally,
the results indicated that LaPSA-38S antigen does not constitute a
target for the humoral response in the different studied groups.
The percentage of positivity was very low ranging from 0% to
12.5%. However, an exception was observed with the aVLiS
group where LaPSA-38S was recognized by 50% of tested sera. In
contrast and as expected, highest positivity was observed using
TSLA antigen. Best results were obtained with sera from
individuals with active VL diseases which 100% react with TSLA
Ldd8.
Discussion
Few vaccine candidates have progressed beyond the experi-
mental stage in animal models of leishmaniasis (mice, hamsters).
This is consistent with the difficulty in developing a suitable animal
model that reproduces the features of the human disease. Direct
extrapolation of data from animal models to human disease is
often controversial and the protective immune responses control-
ling experimental infection may not reflect those required to
prevent leishmaniasis in endemic areas. The purpose of this study
was to evaluate the ability of a PSA antigen to elicit an ex vivo
cellular immune response in PBMC of non exposed and previously
exposed human subjects with and without evidence of protective
immunity. The rationale is that antigens that elicit immune
responses correlating with protection or cure (e.g. significant IFN-c
production in previously exposed and cured individuals) may be
good candidates for prophylactic and/or therapeutic vaccines.
We have previously demonstrated that naturally ESA purified
from culture supernatants of L. infantum promastigotes formulated
with an adjuvant were able to induce a long lasting Th1-mediated
protection against experimental and natural canine VL
[19,32,37,38]. Interestingly, a native soluble L. infantum PSA has
been identified as the active constituent of ESA that reproduce the
observed protective immunity when used as a vaccine in dogs
(unpublished data). PSA is present in both promastigote and
amastigote stages and is over-expressed in stationary phase
parasites [19,32,33]. It is highly conserved in its N-terminal and
C-terminal parts, among Leishmania species, which is a requisite for
ensuring cross-species protection (unpublished data). PSA isolated
from L. amazonensis promastigotes as well as recombinant vaccinia
viruses expressing this protein have been demonstrated to elicit a
protective immune response against infection with L. amazonensis in
BALB/c mice [28,42]. Moreover, PSA-2 polypeptides purified
from L. major and plasmid DNA encoding PSA-2, but not
recombinant PSA-2 purified from E. coli, provided significant
protection against L. major infection in BALB/c mice [29,43]. Our
aim was to identify a human vaccine candidate targeting Leishmania
species that cause CL and VL. We used a recombinant native L.
amazonensis PSA (LaPSA-38S), as a potential candidate vaccine.
Despite the fact that the amino sequence alignment of LaPSA-38S
with PSA proteins from several Leishmania species, shows that these
proteins are not 100% identical, the N-terminal and C-terminal
regions present highly conserved segments. However, the number
of Leucine Rich Repeat motifs located in the central region was
variable [19]. Nevertheless, these proteins belong to the same
unique PSA family according to various well known criteria which
constitute the PSA family unique signature [19]. Thus, all PSA
might be considered as highly similar regarding their protein
primary structure since they correspond to the same architecture
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depicted by a precise domain organization which is well conserved
among PSA from different Leishmania species [19].
LaPSA-38S was produced in a non-pathogenic L. tarentolae
recombinant expression system. This expression system allows the
conservation of Leishmania-type post-translational modifications
including glycosilation, phosphorylation and disulfide bond
formation. Moreover, the L. tarentolae expression system, in
addition to being non-pathogenic to mammals, is an ideal
expression system to produce native proteins of Leishmania [44].
A multi-disciplinary consortium has been set-up including groups
from Europe (France and Spain for L. infantum infection) and from
different endemic countries where both VL and CL are highly
prevalent (India for L. donovani, Peru for L. braziliensis and Tunisia
for L. major and L. infantum infections). We demonstrated that
LaPSA-38S induced similar significant and specific levels of IFN-c
in individuals immune to L. major and L. infantum infection. Healthy
high IFN-c responders had equivalent responses to the cured
group. A non specific IFN-c response to LaPSA-38S stimulation
was observed in L. braziliensis or L. donovani immune individuals.
Analysis of the phenotypes of LaPSA-38S-stimulated T cells
showed a significant increase in the percentage of IFN-c producing
CD4+ T cells detected only in cured individuals. Furthermore, a
strong positive correlation was found between the percentage of
IFN-c-producing CD4+ T cells and the IFN-c production
determined by CBA. Data on the PSA immunogenicity in humans
are scarce. One study has shown that PSA from L. amazonensis was
able to stimulate T cell proliferation in leishmaniasis patients [45].
To our knowledge, only one study reported that PSA from L. major
was able to induce strong proliferative responses and high IFN-c
and TNF-a levels in individuals with a past history of self-healing
CL [30]. Healing from human leishmaniasis is generally associated
with an appropriate Th1 response characterized by IFN-c
Figure 2. Total Soluble Leishmania antigen (TSLA) specific IFN-c, granzyme B, TNF-a responses. IFN-c (Fig. 2a), granzyme B (Fig. 2b), were
detected and quantified from culture supernatants of PBMC exposed for 120h to local TSLA (10 mg/ml) and TSLA Ldd8 (10 mg/ml), by Cytokine Beads
Array test (CBA) using Flow cytometry. Statistically significant differences between stimulated and non stimulated cultures and between groups (p#
0.03) are showed.
doi:10.1371/journal.pone.0092708.g002
Figure 3. LaPSA-38S specific IFN-c, granzyme B, TNF-a and IL-10 responses. IFN-c (Fig. 3a), granzyme B (Fig. 3b), TNF-a (Fig. 3c) and IL-10
(Fig. 3d) were detected and quantified from culture supernatants of PBMC exposed for 120 h to SLA (10 mg/ml) or LaPSA-38S (10 mg/ml) using
Cytokine Beads Array test (CBA). Data were analyzed by Flow cytometry. PHA (10 mg/ml) was used for all cultures as positive control (data not shown).
Statistically significant differences between stimulated and non stimulated cultures (p#0.003) and between groups (p#0.01) are showed.
doi:10.1371/journal.pone.0092708.g003
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Figure 4. Phenotype of IFN-c producing cells. PBMC were stimulated with PMA (50 ng/ml)/ionomicyn (1026 M) or PHA (10 mg/ml) for 6 h
(positive controls), TSLA Ldd8 (10 mg/ml) or LaPSA-38S (10 mg/ml) for 120 h. For intracellular IFN-c detection, cells were treated with Golgistop for the
last 6 hours of culture, fixed and permeabilized using BD Cytoperm/cytofix kit, and analyzed by flow cytometry. Results represent the frequency of
IFN-c producing cells within the CD3+CD4+CD69+ and CD3+CD8+CD69+ cell populations. * Statistically significant differences from stimulated and non
stimulated cultures (p,0,05).
doi:10.1371/journal.pone.0092708.g004
Table 3. Total IgG prevalence against LaPSA-38S in different endemic areas of leishmaniasis.
Endemic Area Ig Group of individuals Tested sera Percentage of positive sera (%)
SLA LaPSA
India Total IgG CVLd 13 92,3 -
aVLd 25 100 8
HLR-I 9 - -
Peru Total IgG CCLb 9 - -
aCLb 21 4,8 -
HLR-P 10 - -
Tunisia Total IgG CCLm 19 68,4 5,3
HHR-Lm 20 15 5
HHR-Li 15 40 6,7
aVLiT 12 100 -
HLR-T 17 5,9 5,9
France IgG HHR-Li F 8 12,5 12,5
HLR-F 28 - 3,5
Spain IgG HHR-Li S 9 - -
HLR-S 9 - 11,11
aVLiS 4 100 25
The cut-off value of reactivity for LaPSA-38S antigen was calculated as the mean plus 3 SD of the OD values observed in naive controls from each country. These cut-off
values allowed us to distinguish between positive and negative sera and consequently to estimate performance parameters of each ELISA test.
doi:10.1371/journal.pone.0092708.t003
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production. Thus, our finding showing that LaPSA-38S stimulates
high levels of IFN-c in individuals with immunity to L. major or L.
infantum infection, suggests that this protein may be associated with
protective immunity. With regard to IL-10 production, we showed
that, in addition to its Th1 response-inducing activity, LaPSA-38S
induces significant IL-10 levels in individuals with immunity to L.
major or L. infantum infection, and to a lesser extent in naı¨ve groups.
IL-10 is an anti-inflammatory cytokine with broad immune-
regulatory functions, produced by different cell populations
including dendritic cells, macrophages, Th2 and different regula-
tory CD4+ T subsets [46]. The regulatory effects of IL-10 on
immune responses and pathology have been frequently reported
[47]. Heterogeneity of CD4+ T cell cytokine response has
complicated the definition of the immune correlates of vaccine-
mediated protection [48]. Recently, the balance between pro-
inflammatory IFN-c/TNF-a and regulatory IL-10 cytokines has
been shown to be involved in the outcome of human leishmaniasis
and in the prediction of vaccine success [17]. Therefore, the
capacity of LaPSA-38S to induce IL-10 does not exclude this
protein as a potential candidate vaccine. We also detected
significant and specific levels of granzyme B in L. major and L.
infantum immune individuals. Very few reports have investigated
the involvement of granzyme B in human leishmaniasis. While an
increase of granzyme B activity have been associated with a good
prognosis in human CL caused by L. major or L. mexicana, [49,50],
CD8+ granzyme B+ T cells have been reported to mediate tissue
injury in CL caused by L. braziliensis [51]. Granzyme B is a serine
protease expressed in human T CD8+ and T CD4+ cells as well as
in Treg cells [52]. It has been first implicated in apoptosis of target
cells [53]. Recently, several studies have highlighted a new
inflammatory role of granzyme B through the regulation of
cytokine expression and processing and regulatory T cells activity
[53-56]. To our knowledge, this is the first description of a
Leishmania antigen-induced granzyme B response in humans
immune to Leishmania infection. The increase of granzyme B, in
response to a heterologous prime boost vaccination of mice using
the LACK p36 antigen suggests its contribution to the disease
control [57]. Our data also show strong positive correlations
between granzyme B and IFN-c levels in response to LaPSA-38S,
in individuals with cured L. major CL, which could be associated
with protective immunity.
We also showed in our study that LaPSA-38S induced a mixed
Th1 and Th2/Treg cytokine profile in individuals with immunity
to L. major and L. infantum infection but not in individuals with
immunity to L. braziliensis or L. donovani. Data on conserved
Leishmania antigens enabling cross-species protection were reported
in murine models [58–60]. However, absence of cross-species
protection was more frequently described [61–63]. The absence of
cross-protection between Leishmania species could be explained by
the biological differences between Leishmania species and by the level
of sequence homology of the Leishmania proteins used. Indeed,
while the L. major and L. infantum proteins-coding sequences are
conserved, the new world L. braziliensis proteins-coding sequences
are more divergent [64]. Finally, humoral responses analysis
results clearly show that LaPSA-38S antigen did not induce a
significant antibody response in individuals that display different
clinical manifestations and forms of leishmaniasis. These results
are in accordance with other studies describing reactivities of
human VL sera to PSA antigen [32]. However, in our case, we
cannot exclude that this low recognition may be due to the amino-
acids sequence divergence between LaPSA-38S (used in our
experiment) and PSA from L. major, L. infantum and L. donovani. In
conclusion, we have demonstrated here that, in spite of differences
in disease forms induced by L. major and L. infantum, the LaPSA-
38S protein was able to induce a similar Th1 and Th2/Treg
profile in individuals immune to infection by these two species. To
our knowledge, this is the first description of PSA-induced IFN-c,
granzyme B, TNF-a and IL-10 response in humans with immunity
against L. major and L. infantum infection. The capacity of LaPSA-
38S to induce mixed Th1 and Th2/T regulatory responses is an
argument for the use of this protein as a potential candidate
vaccine. Our approach to investigate the ability for a given
antigen, to elicit cellular protective responses in human popula-
tions from different endemic areas may help to select vaccine
candidates and to prioritize antigens for clinical development of a
subunit vaccine against leishmaniasis.
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